Introducing Landmark Bio and Appointment of Ran Zheng as CEO
2021-07-29
Zheng will lead the construction of the new, state-of-the-art biomanufacturing facility that
kicks off today (July 29) in Watertown, MA and will begin opening in 2022.
WATERTOWN, MA (July 29, 2021) – Landmark Bio™ announced today the appointment of Ran Zheng as Chief Executive Officer. Ms. Zheng is a biotechnology industry veteran who brings more than 25 years of experience in biotechnology operations across multiple geographies to Landmark Bio. Previously known as the center for advanced biological innovation and manufacturing (or “CABIM”), the mission of this newly created public benefit company is to help new therapeutics reach patients faster while strengthening Massachusetts’ position as the world’s life science capital.
In this role, Ms. Zheng will stand up the new facility, establish core capabilities, recruit and build a diverse, talented team of ultimately more than 100 experts focusing on the emerging technologies of cell and gene therapies, mRNA, and other novel modalities with the support of the company’s founding partners and board members, which include leaders from Harvard University, Massachusetts Institute of Technology (MIT), Cytiva, FUJIFILM Diosynth Biotechnologies, and Alexandria Real Estate Equities, Inc.
read more